Cargando…
Ferroptosis in cancer and cancer immunotherapy
The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822596/ https://www.ncbi.nlm.nih.gov/pubmed/35133083 http://dx.doi.org/10.1002/cac2.12250 |
_version_ | 1784646630015762432 |
---|---|
author | Zhao, Lei Zhou, Xiaoxue Xie, Feng Zhang, Lei Yan, Haiyan Huang, Jun Zhang, Chong Zhou, Fangfang Chen, Jun Zhang, Long |
author_facet | Zhao, Lei Zhou, Xiaoxue Xie, Feng Zhang, Lei Yan, Haiyan Huang, Jun Zhang, Chong Zhou, Fangfang Chen, Jun Zhang, Long |
author_sort | Zhao, Lei |
collection | PubMed |
description | The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry. The broad spectrum of injury and tumor tolerance are the main reasons for radiotherapy and chemotherapy failure. The effective rate of tumor immunotherapy as a new treatment method is less than 30%. Ferroptosis can be seen in radiotherapy, chemotherapy, and tumor immunotherapy; therefore, ferroptosis activation may be a potential strategy to overcome the drug resistance mechanism of traditional cancer treatments. In this review, the characteristics and causes of cell death by lipid peroxidation in ferroptosis are briefly described. In addition, the three metabolic regulations of ferroptosis and its crosstalk with classical signaling pathways are summarized. Collectively, these findings suggest the vital role of ferroptosis in immunotherapy based on the interaction of ferroptosis with tumor immunotherapy, chemotherapy and radiotherapy, thus, indicating the remarkable potential of ferroptosis in cancer treatment. |
format | Online Article Text |
id | pubmed-8822596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88225962022-02-11 Ferroptosis in cancer and cancer immunotherapy Zhao, Lei Zhou, Xiaoxue Xie, Feng Zhang, Lei Yan, Haiyan Huang, Jun Zhang, Chong Zhou, Fangfang Chen, Jun Zhang, Long Cancer Commun (Lond) Reviews The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry. The broad spectrum of injury and tumor tolerance are the main reasons for radiotherapy and chemotherapy failure. The effective rate of tumor immunotherapy as a new treatment method is less than 30%. Ferroptosis can be seen in radiotherapy, chemotherapy, and tumor immunotherapy; therefore, ferroptosis activation may be a potential strategy to overcome the drug resistance mechanism of traditional cancer treatments. In this review, the characteristics and causes of cell death by lipid peroxidation in ferroptosis are briefly described. In addition, the three metabolic regulations of ferroptosis and its crosstalk with classical signaling pathways are summarized. Collectively, these findings suggest the vital role of ferroptosis in immunotherapy based on the interaction of ferroptosis with tumor immunotherapy, chemotherapy and radiotherapy, thus, indicating the remarkable potential of ferroptosis in cancer treatment. John Wiley and Sons Inc. 2022-02-08 /pmc/articles/PMC8822596/ /pubmed/35133083 http://dx.doi.org/10.1002/cac2.12250 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Zhao, Lei Zhou, Xiaoxue Xie, Feng Zhang, Lei Yan, Haiyan Huang, Jun Zhang, Chong Zhou, Fangfang Chen, Jun Zhang, Long Ferroptosis in cancer and cancer immunotherapy |
title | Ferroptosis in cancer and cancer immunotherapy |
title_full | Ferroptosis in cancer and cancer immunotherapy |
title_fullStr | Ferroptosis in cancer and cancer immunotherapy |
title_full_unstemmed | Ferroptosis in cancer and cancer immunotherapy |
title_short | Ferroptosis in cancer and cancer immunotherapy |
title_sort | ferroptosis in cancer and cancer immunotherapy |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822596/ https://www.ncbi.nlm.nih.gov/pubmed/35133083 http://dx.doi.org/10.1002/cac2.12250 |
work_keys_str_mv | AT zhaolei ferroptosisincancerandcancerimmunotherapy AT zhouxiaoxue ferroptosisincancerandcancerimmunotherapy AT xiefeng ferroptosisincancerandcancerimmunotherapy AT zhanglei ferroptosisincancerandcancerimmunotherapy AT yanhaiyan ferroptosisincancerandcancerimmunotherapy AT huangjun ferroptosisincancerandcancerimmunotherapy AT zhangchong ferroptosisincancerandcancerimmunotherapy AT zhoufangfang ferroptosisincancerandcancerimmunotherapy AT chenjun ferroptosisincancerandcancerimmunotherapy AT zhanglong ferroptosisincancerandcancerimmunotherapy |